PITTSBURGH, July 14, 2025 – Longevity Health Holdings, Inc. (Nasdaq: XAGE) has taken a significant step by entering a merger agreement with True Health Inc., known for its THPlasma brand in the plasma collection industry. This all-stock deal will allow both companies to trade on Nasdaq under XAGE after the merger closes.
Along with this, Longevity has mutually ended its transaction with 20/20 BioLabs. This merger follows Longevity’s earlier acquisitions: Carmell Therapeutics, which focuses on plasma-derived growth factors, and Elevai Skincare, based on stem cell technology.
The U.S. currently supplies over 60% of the world’s plasma, yet faces a shortfall in plasma-derived therapies, including essential treatments like immunoglobulins and clotting factors. THPlasma aims to tackle this issue through a growing network of plasma collection centers.
### THPlasma’s Growth Highlights:
– Plans to increase centers from 2 in New Jersey to 5 across New Jersey and Pennsylvania by FY25.
– Secured $100 million in annual sales through off-take agreements.
– Achieved cash profitability in FY2024.
– Estimated FY2025 revenues of $10 million with an EBITDA of $2 million.
– Projected FY2026 revenues of $32 million, indicating a 220% growth year-over-year.
### Transaction Details:
– THPlasma’s valuation stands at $59 million, with an additional $20 million tied to financial performance.
– Longevity’s stock is valued at $3.00, representing a 12% premium over its previous close.
Both companies are excited about the merger. George Chi, Founder and CEO of THPlasma, expressed optimism, stating that this move will enhance growth and unlock public market opportunities. Rajiv Shukla, Longevity’s Chairman and CEO, noted the merger as a pivotal moment for shareholder value.
### About the Companies:
THPlasma operates plasma collection centers in the Northeast, backed by strong sales partnerships. Longevity Health Holdings focuses on healthy aging and longevity, integrating the latest scientific advancements in health and wellness.
This merger reflects a significant trend in the health and tech sectors, where companies are increasingly merging to capitalize on shared resources and enhance market offerings. According to a report from Deloitte, mergers in healthcare have been rising, as companies seek to innovate in therapeutic solutions and improve patient access.
As Longevity and THPlasma combine forces, the public will be keenly watching for the impact on their operations and the broader healthcare landscape.
Source link
Nasdaq:XAGE, Longevity Health Holdings, Inc., Merger, Longevity Health Holdings, THPlasma, 20/20 Biolabs
